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Abstract
Mutations in PLA2G6 gene have variable phenotypic outcome including infantile neuroaxonal dystrophy, atypical
neuroaxonal dystrophy, idiopathic neurodegeneration with brain iron accumulation and Karak syndrome. The cause
of this phenotypic variation is so far unknown which impairs both genetic diagnosis and appropriate family
counseling. We report detailed clinical, electrophysiological, neuroimaging, histologic, biochemical and genetic
characterization of 11 patients, from 6 consanguineous families, who were followed for a period of up to 17 years.
Cerebellar atrophy was constant and the earliest feature of the disease preceding brain iron accumulation, leading to
the provisional diagnosis of a recessive progressive ataxia in these patients. Ultrastructural characterization of
patients’ muscle biopsies revealed focal accumulation of granular and membranous material possibly resulting from
defective membrane homeostasis caused by disrupted PLA2G6 function. Enzyme studies in one of these muscle
biopsies provided evidence for a relatively low mitochondrial content, which is compatible with the structural
mitochondrial alterations seen by electron microscopy. Genetic characterization of 11 patients led to the identification
of six underlying PLA2G6 gene mutations, five of which are novel. Importantly, by combining clinical and genetic data
we have observed that while the phenotype of neurodegeneration associated with PLA2G6 mutations is variable in
this cohort of patients belonging to the same ethnic background, it is partially influenced by the genotype, considering
the age at onset and the functional disability criteria. Molecular testing for PLA2G6 mutations is, therefore, indicated
in childhood-onset ataxia syndromes, if neuroimaging shows cerebellar atrophy with or without evidence of iron
accumulation.
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Introduction
Neurodegeneration associated with PLA2G6 mutations
(PLAN) constitutes a heterogeneous group of clinical entities
which encompasses infantile neuroaxonal dystrophy (INAD1/
NBIA2A, MIM # 256600), atypical neuroaxonal dystrophy
(NAD), idiopathic neurodegeneration with brain iron
accumulation including Karak syndrome (NBIA2B, # MIM
610217) [1-9] and the recently reported syndrome of adult-
onset dystonia-Parkinsonism (PARK 14, MIM # 612953) [9].
PARK 14 is characterized by rapidly progressive young-adult
onset Parkinsonism associated with dystonia, cognitive decline
and cerebral atrophy on MRI [9]. Onset may vary between 4
and 30 years, and abnormal brain iron may not be evident on
MRI studies until late in the disease course [10-12].
INAD1/NBIA2A caused by mutations in PLA2G6 gene starts
typically between ages 6 months and 3 years with rapid
progression of truncal hypotonia, progressive psychomotor
delay, cerebellar ataxia, symmetric pyramidal tract signs and
tetraparesis (usually spastic but sometimes areflexic). Children
commonly manifest strabismus, nystagmus and optic atrophy,
and lose the ability to walk shortly after attaining it or never
learn to walk [4,6]. INAD is pathologically characterized by the
presence of spheroids in both the central and peripheral
nervous system [4,6,13].
Onset of atypical NAD is later than the one observed in INAD
(about 4 years of age). Phenotype includes gait instability and
delayed speech in >50% of patients, progressive dystonia and
dysarthria, optic atrophy, tetraparesis (spastic or areflexic), and
neurobehavioral disturbances. Neuroimaging reveals presence
of cerebellar atrophy as early as at 2-3 years of age with no
associated signs of iron deposition in the globus pallidus.
Nevertheless, brain iron accumulation became obvious later
and constitutes one of the diagnostic criteria [4]
Karak syndrome was described in two adolescent siblings
with mutations in PLA2G6 gene who suffered, since age 6
years, from slowly progressive ataxia associated with cognitive
decline. Choreiform movements were evident by 9 years and
ambulation was lost by 10 years [1]. Although both patients had
normal motor power, pyramidal signs in addition to cerebellar
and extrapyramidal signs were evident. On MRI, they had
moderate degree of cerebellar atrophy, accumulation of iron in
the substantita nigra, as well as a central hyperintensity within
a region of hypointensity in the medial globus pallidus (the eye-
of-the-tiger-sign).
PLA2G6 gene encodes iPLA2-VIA, one of several calcium-
independent phosphatases, which catalyzes the hydrolysis of
glycerophospholipids, generating a free fatty acid, usually
arachidonic acid, and a phospholipid [14]. Through altering the
phospholipid composition of cellular and subcellular
membranes, defects in iPLA2-VIA lead to failure to repair
oxidative damage to membrane phospholipids and adversely
affect membrane fluidity, permeability or iron homeostasis. This
results in structural damage of the membrane and neuronal
apoptosis, which may underlie the axonal pathology and brain
iron accumulation [14,15].
Here we report the clinical, electrophysiological,
neuroimaging, neuropathological and genetic features of 11
patients from 6 consanguineous families of ethnic Arab
background suffering from NBIA syndromes associated with
PLA2G6 gene mutations, and followed for a maximum period
of 17 years.
Patients and Methods
Ethics Statements
Clinical evaluation, blood and muscle biopsy samples were
obtained specifically for this study after a written informed
consent, as defined by the local Ethics Committee-Deanship of
Scientific Research College of Medicine Research Center
(CMRC), King Saud University, Riyadh, according to the
principles of the declaration of Helsinki. The ethics committee
specifically approved this study.
Clinical investigations
Eleven patients (5 males and 6 females) from 6
consanguineous Saudi Arabian families were studied. Ten of
these were evaluated at the Division of Pediatric Neurology,
King Khalid University Hospital, and College of Medicine, King
Saud University, Riyadh, from October 1993 to February 2011.
One patient was seen and investigated at King Faisal
Specialist Hospital and Research Centre, Riyadh. All patients
were examined by a neurologist, an ophthalmologist and a
neuro-ophthalmologist to document clinical status at the time of
enrolment.
Neurophysiological studies
Standard EEG recordings were done for three patients who
had epilepsy, and another two who were asymptomatic. Nerve
conduction studies were performed and recorded in all patients
except one (F4 [P1]), following a conventional protocol [16]
using surface electrodes and stimulator. Age-appropriate
reference values were utilized for interpretation [17-19]. Motor
conduction study in the upper limbs was done for the median
nerve in 7 and for the ulnar nerve in 2 patients, while it could
not be performed in one patient (F1 [P1]), because of the
presence of bedsores and contracture deformities.
Neuro-ophthalmic and neuroimaging examinations
Ophthalmologic examinations were occasionally limited
because many of the patients were young and because of the
cognitive complications of the neurodegenerative disorder. The
assessment of optic disk pallor was done using indirect
ophthalmoscopy. All patients had visual evoked responses
(VEPs) using flashing lights and P100 was the most important
wave to identify. All patients had brain computer tomography
(CT) and/or magnetic resonance imaging (MRI) [Siemens 1.5
Tesla].
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Structural and functional muscle analysis
Muscle biopsy (from the vastus lateralis) was undertaken in 4
patients and examined by standard histological techniques.
Two glutaraldehyde-fixed muscle specimens were available for
electron microscopy (EM) examination and processed as
described by Weis et al. [20]. The quantification of
intermyofibrillar mitochondria was done manually on 10 digital
electron micrographs taken of randomly selected fields of the
specimens with the magnification of 6000X [21]. In one biopsy,
mitochondrial enzyme activities were measured in crude
muscle extracts as described [22,23].
Other investigations
Prior to the molecular diagnosis, detailed investigations were
undertaken to rule out inborn errors of metabolism, progressive
ataxia syndromes and/or mitochondrial disorders, and all were
within normal limits. These tests included measurements for
renal, hepatic, thyroid functions, creatine-phosphokinase, blood
glucose, ammonia, lactate, pyruvate, Tandem metabolic
screen, biotinidase, triglycerides and cholesterol, isoelectric
focusing of transferrin, very long chain fatty acids, serum
copper and ceruloplasmin, serum vitamins E and B12, ∝-
fetoprotein and carcinoembryonic antigen, antinuclear
antibodies, karyotype, bone marrow aspirate, urinary amino
acids, organic acids and sulfocysteine-xanthine, and CSF
glucose, proteins and lactate. Because ataxia was the earliest
presenting clinical sign, prior to start genotyping of the families,
two patients have had molecular investigations for Friedreich
ataxia and no abnormal GAA expansion was found in FXN
gene (data not shown).
Genetic and bioinformatics analysis
Genotyping of 5 out of 6 families was performed using 10
microsatellite markers ([D20S: 842, 181, 867, 116, 482 and
8959] and [D22S:1177, 1045, 272 and 428]) flanking the
PANK2 and PLA2G6 genes, respectively. PCRs were
performed using classical procedures. The PCR products were
analysed on an ABI 3730 automatic sequencer (Applied
Biosystems). The genotypes were determined using
GeneMapper version 4 software (Applied Biosystems) and the
haplotypes were reconstructed manually. Allegro software [24]
was used for multipoint LOD scores calculations. Mutation
analysis in the PLA2G6 gene was done by specific PCR
amplification of all exons and their flanking intron segments
(primers and annealing conditions available upon request) in a
Veriti thermal cycler (Applied Biosystems) followed by direct
sequencing with Big Dye terminator chemistry in an ABI3730
sequencer, according to the manufacturer’s recommendations
(Applied Biosystems). Sequences were analysed using
Seqscape 2.6 software (Applied Biosystems). In addition, 86 to
175 North African unrelated healthy subjects were screened to
evaluate the frequency of the mutations. Gene rearrangements
in PLA2G6 and PANK2 were analyzed using the specific
Multiplex Ligation-dependent Probe Amplification (MLPA) kit #
P120 (MRC-Holland) with the ABI3730 sequencer and analysis
of the electrophoretic profiles with GeneMapper 4 (Applied
Biosystems). Deleterious defects of missense variants were
analyzed with the SIFT, PolyPhen2 (http://
genetics.bwh.harvard.edu/pph) Multiple alignments of orthologs
of PLA2G6 for the analysis of the conservation of affected
amino acids in various species were done with PolyPhen2.
Results
Symptoms and signs
All affected individuals had normal perinatal history and early
developmental milestones within the first 9 months of life.
Three children (F1 [P1], F2 [P1 and P2]) [Table 1] never
walked; but the other 8 were able to walk at a mean age of 13
months (median 12 months, range 12-16 months). Ataxia was
the earliest appearing symptom (Table 1) at a median age of
14 months (mean=29.6 months, range 9 months-6 years). This
was followed by motor and cognitive decline in all patients, but
with varying pace. Except for the 3 patients who never walked
and another (F6 [P2], Table 1) who was still walking until age
20 years and lost ambulation at 20.5 years, all other patients
became wheelchair-bound at a median age of 6 years
(mean=9.5 years, range 3-17 years). Psychiatric symptoms
were evident in 5 (45%) patients. Two siblings (F6 [P2 and P1])
had episodes of phobias and panic attacks, a third child (F6
[P4]) experienced bouts of rage at home, the forth (F1 [P1]),
had episodes of self-mutilation, whereas the fifth (F2 [P2]) had
bouts when he became frightened. One patient [F6 (P1)]
developed complex partial seizures at the age of 21 years, and
was well-controlled with lamotrigine. Two siblings (F2 [P1 and
P2]) had seizures starting at 18 months. These were
infrequent, brief (less than 1 minute) and consisted of blue
spells associated with body stiffness.
Physical examination [Table 2] revealed microcephaly (head
circumference <2SD) in 3 (27%) patients and strabismus was
evident in 5 (45%). Optic nerve pallor was seen in 9 (82%) and
was associated with strabismus in 4 (36%). All patients showed
nystagmus or saccadic pursuit. When assessed at a median
age of 10 years (mean = 12.0 years; range 2.4-27 years), leg
stiffness was apparent in 5 (45%) patients and 9 (82%) showed
hyperreflexia of the upper and/or lower limbs. Extrapyramidal
signs in the form of facial dyskinesia, dystonia, bradykinesia
and/or rigidity were observed in 7 (64%) patients. Contracture
deformities of the limbs, including heelcord tightening and
equinovarus, were ascertained in 8 (73%), and 2 (18%)
patients had severe scoliosis. Other complications which
developed over the years included multiple bed sores and
osteomyelitis in a 27-year-old female (F6 [P1]), and
malnutrition (requiring feeding through gastrostomy tube) and
bed sores in another girl aged 9.8 years (F1 [P1]). Two patients
died at ages of 12.8 years (F3 [P1]) and 28 years (F6 [P1]).
The causes of death were, respectively, respiratory infection
due to H1N1 swine flu and septicaemia following bed sores.
Visual evoked potential (VEP) and
electroencephalography (EEG)
Absent or delayed evoked potentials (VEP) were seen in
5/11 (45%) patients (Table 3). In the patient who developed
clinical seizures at the age of 21 years (F6 [P1]), EEG showed
normal background activity associated with frequent sharp,
spike and slow-wave complexes seen on the left anterior
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frontal region. The elder of the two siblings with clinical
seizures (F2 [P1]) had normal EEG; whereas the younger one
(F2 [P2]) had non-specific generalized slow activity, more on
the occipital electrodes. Another asymptomatic child (F4 [P1]),
had excessive fast beta activity associated with predominantly
right occipital and generalized epileptiform discharges. Diffuse
fast activity over both hemispheres was seen in a third child
(F1 [P1]) who had no clinical seizures.
Nerve conduction studies
Distal axonal-type sensorimotor neuropathy was evident in 9
(90%) patients who had nerve conduction studies (NCS,
[Tables 3 and 4]). Motor nerve conduction velocities (MNCVs)
in the upper limbs were normal in 7 (78%) out of 9 tested
patients and reduced in 2 (22%) [mean = 55.2± 9.12 m/s]. In
the lower limbs, MNCVs were normal in 8 (80%) and
unobtainable in 2 (20%) patients (mean = 49.25 ± 6.81 m/s,
Table 4). In the upper limbs, the distal motor nerve latencies
(DML) were within the normal range in all the 9 tested patients
(100%) while those of the peroneal, done in 10 patients, were
absent in 2 (20%) and prolonged in 3 (30%) patients.
The compound muscle action potentials (CMAPs)
morphology was diphasic and the peak amplitudes were
recorded. With the exception of one (F5 [P1]), all patients had
either unobtainable or low amplitude CMAPs for the peroneal
nerve, recorded from the extensor digitorum brevis (EDB)
muscle; while in the upper limbs 3/9 patients (33%) showed
normal CMAP amplitudes. The median sensory nerve action
potentials (SNAPs) recorded in 9 patients were normal in 7
(77%) and reduced in one (F6 [P2]), while sural SNAPs were
within the normal range in 4/10 (40%) patients.
Neuroradiological features
Brain imaging (Table 5) was undertaken in all patients and
consisted of MRI in 9 (82%), CT in one (F6 [P4]) and CT and
MRI in another patient (F1 [P1]). The first neuroimaging was
performed at a median age of 4.3 years (mean = 7.9 years;
range 1.3-19 years). Four (36%) patients had repeated MRI.
Cerebellar cortical atrophy was universally present even at the
age of 1.3 year (Figure 1). Of the 9 initial MRI scans with
suitable quality, 6 (67%) revealed cerebellar cortical gliosis at a
median age of 7.3 years (mean =7 years; range = 2.8-11.3
years). This manifested as high signal on either T2-weighted or
fluid-attenuated inversion recovery (FLAIR) (Figure 2).
Eight (80%) of the 10 children who had MRI scans showed
evidence of increased iron deposition in the globus pallidus,
seen as reduced signal on T2, FLAIR and/or diffusion weighted
image (DWI) sequence in the initial scans (Figures 3 and 4).
One child (F5 [P1]) (Figure 2) did not have the changes in the
globus pallidus on the initial image performed at the age of 4.2
years, but showed it later at the age of 7.5 years. Another three
children showed globus pallidus changes only on DWI at ages
of 2.8 years (F4 [P1]), 3.1 years (F1 [P1]) and 3.3 years (F2
[P1]), respectively (Table 5). Repeated MRI, performed 13
months later in one of them (F1 [P1]) (Table 5 and Figure 4),
showed the pallidal changes in both T2 and DWI sequences.
An adolescent (F6 [P4]), who was subjected only to CT
performed at 19 years of age, showed cerebellar atrophy with
Global Phenotype Study of PLA2G6 Gene Mutations
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no evidence of globus pallidus changes (in the form of reduced
density). His affected brother (F6 [P3]) showed clear features
of brain iron deposition on MRI done at a younger age (17.4
years, Figure 3). Overall, the initial or only MRI scans, done for
10 patients at median age of 4.3 years (mean = 6.8 years;
range = 1.3-17.4 years), revealed globus pallidus iron
deposition in 8 (80%) whereas cerebellar atrophy was shown in
all patients.
Increased iron in the substantia nigra was revealed by the
initial MRI in 6 of 10 (60%) patients at a median age of 10.3
years (mean = 9.5 years; range = 3.1-17.4 years). Three of the
patients with initial normal substantia nigra signal had their MRI
at 1.3 year (F2 [P2]), 2.8 years (F4 [P1]), and 3.3 years (F2
[P1]) but no subsequent scans. The fourth patient (F5 [P1]),
had his initial MRI at the age of 4.2 years, but showed
substantia nigra iron deposition when imaging was repeated 3
years 4 months later (Table 5). With imaging allowing adequate
assessment, 6 of 10 (60%) patients had cerebral white matter
changes and one of them (F6 [P1]), also showed cerebral
atrophy at the age of 21.3 years. Abnormality of corpus
callosum was detected in 2 of 10 (20%) patients, at 4.2 years in
the first one (F1 [P1]), and was borderline in the second (F5
[P1]) at the same age with abnormality detected 3 years and 4
months later. This consisted of simple appearance to the
splenium which was thin and elongated. The initial MRI in the
other patients showed normal corpus callosum (Table 5,
Figures 3 and 4).
Structural and functional analysis of muscle biopsies
Histological examination of muscle biopsies from 4 patients
revealed non-specific neurogenic features. In contrast, electron
microscopy (Figure 5) revealed significant abnormalities in the
two examined muscle specimens. Alterations in the muscle
biopsy (taken at the age of 12 years) of patient F6 (P1) with
Karak syndrome phenotype (Table [1.1 and 2.1] and Figure 5)
consisted of enlargement of the sarcoplasmic space between
myofibrils associated with focal increase in granular and
membranous material. There were no myonuclear inclusions.
Biochemical assay of muscle enzymes of this patient [F6 (P1)]
revealed a remarkably low activity of all mitochondrial enzymes
measured. These included NADH: Q1 oxidoreductase
(complex I) of 3.5 mU/mg (control range = 12.5-19.5),
succinate: cyt c oxidoreductase (complex II + coenzyme Q +
complex III) of 4.0 mU/mg (control range = 8.2-44), and
decylubiquinol: cyt c oxidoreductase (complex III) of 41 mU/mg
Table 2. Clinical features of 11 patients with PLA2G6 gene mutations.
 Family (Patient No.)
 F1 (P1) F2 (P2) F2 (P1) F3 (P2) F3 (P1) F4 (P1) F5 (P1) F6 (P3) F6(4) F6 (P1) F6 (2)
Strabismus Yes None None None None Yes Yes None None Yes Yes
Optic nerve
pallor Yes (OU) None Yes (OU) Yes (OU)
Yes
(temporal
OU)
Yes
(OU) None
Yes
(OU)
Yes
(temporal
OU)
Yes (OU) Yes (OU)
Nystagmus /
saccadic pursuit Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Extrapyramidal
signs
UL (NA) LL
(None) None
Rigidity
throughout
elbow
movement
Mild
rigidity
(UL)
Dystonia,
facial
dyskinesia,
rigidity
None Bradykinesia(UL)
Slight
rigidity None
Dystonia,
facial
dyskinesia,
rigidity
Rigidity
Deep tendon
reflexes Brisk (UL)
Brisk
(UL +
LL)
Brisk (UL and
knees) Present
(ankles)
Brisk (UL
+ knees) Brisk (UL)
Brisk
(UL +
LL)
Brisk (UL +
knees)
Absent
(UL) Absent (UL)
Brisk (UL +
knees) Brisk
 Absent (LL)   Absent(ankles) Absent (LL)   
Absent
(LL) Absent (LL)
Absent
(ankles)
(UL + knees)
Absent
(ankles)
Sensation
(crude touch) N N N N N N N N N N N
Contracture
deformities
Multiple flexion
contracture
deformities (UL
+ LL) Severe
scoliosis
None Equinovarus Heel cordtightening
Equinovarus
Severe
scoliosis
None Heel cordtightening None Equinovarus Equinovarus Equinovarus
Other
complications
(surgical
operations)
Malnutrition
bed sores
(Gastrostomy
tube fixed)
 
(Tonsillectomy &
adenoidectomy
at 2y because of
snoring at night)
None None None
None (Medial
hamstring and
tendoachilis
release
bilaterally)
None None
Multiple bed
sores osteo-
myelitis
None
doi: 10.1371/journal.pone.0076831.t002
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(control range = 54-434). Citrate synthase activity was at the
lowest reference value (48 mU/mg; control range = 48-162). By
contrast, the ratios between enzyme activity of the respiratory
chain and citrate synthase were not remarkable. The relatively
low activity of all enzymes on protein base, combined with the
normal enzyme activity ratio’s, lead us to conclude that there is
a relatively low mitochondrial content in the muscle of patient
[F6 (P1)], rather than a deficiency of one or more respiratory
chain enzymes. To confirm these results we determined the
density of the intermyofibrillar mitochondria in the patient’s [F6
(P1)] biopsy and compared it to an age and gender matched
healthy individual’s muscle specimen taken from the same
location (vastus lateralis muscle) using electron microscopy.
We found that the patient’s muscle showed a significant
decrease in the mitochondrial density (0.255 +/- 0.05/µm2) in
comparison to the control (0.379 +/- 0.06/µm2) (p=0.0001).
Electron microscopic analysis of the muscle biopsy (taken at
the age of 3 years) of patient F1 (P1) [Table 1 and 2.1 and
Figure 5] with INAD phenotype showed moderately increased
lipid droplets in muscle fibres; both in size and numbers. There
was also subsarcolemmal accumulation of membranous
material indicating proliferation of sarcoplasmic reticulum
membranes.
Molecular genetics
Genotyping allowed us to exclude the PANK2 gene for 5
families while all the affected members of these were
homozygous for the microsatellite markers flanking the
PLA2G6 locus (Figure 6). In accordance with the genotypes,
pairwise and multipoint LOD scores were positive for each
family and a maximum value of + 3.39 was reached in the
largest pedigree (F6) [Table 6].
Sequencing of the PLA2G6 gene allowed us to identify six
different homozygous mutations perfectly segregating with the
disease in the corresponding family members (n = 35). All
affected individuals were homozygous for the identified
mutation while parents, for whom the DNA was available, were
heterozygotes for the mutations and unaffected siblings were
either heterozygotes or homozygous for the wild type allele
(Figure 6). Five mutations, 2 missense (p.H225Y and p.G740R)
and 3 truncating (p.E375EfsX389, p.S637RfsX29 and
p.R654X) were newly identified. The additional missense
mutation (p.R591Q) found in family F3 has already been
reported [2,4]. The missense mutations p.H225Y and p.G740R
were not found in at least 86 [range 86-175] North-African
controls. Moreover, none of the six mutations we identified in
this study was found in more than 5,352 controls from Exome
variant Server (http://evs.gs.washington.edu/EVS/) (Table 7).
The three truncating mutations (the nonsense one and the 2
Table 3. Neurophysiological tests and muscle biopsy characterization.
 Family (Patient No.)
 F1 (P1) F2 (P2) F2 (P1) F3 (P2) F3 (P1) F4 (P1) F5 (P1) F6 (P3) F6 (P4) F6 (P1) F6 (P2)
Gender F M F M F F M M M F F
NCS (Table 4) Axonalneuropathy
Axonal
neuro-
pathy
Axonal
neuro-pathy
Axonal
neuro-
pathy
Axonal
neuropathy ND
Essentially
Normal
Axonal
neuropathy
Axonal
neuropathy
Axonal
neuropathy
Axonal
neuropathy
VEP (flash) Normal
No
response
(OU)
No response
(OU)
Delayed
P100 (R
& L)
Normal (R)
Delayed
P100(L)
Normal Normal Normal Normal
No response
(R) Delayed
P100 (L)
Normal
EEG
Diffuse fast
activity
over both
hemi-
spheres
* WNL ND ND ** ND ND ND
Frequent
sharp,
S&SLW
complexes
on L anterior
frontal
ND
Muscle
biopsy Histochemistry
Non-
specific
neurogenic
changes
ND
Non-
specific
neurogenic
changes
ND ND ND ND ND ND
Non-
specific
neurogenic
changes
Non-
specific
neurogenic
changes
 ElectronMicroscopy *** ND ND ND ND ND ND ND ND § ND
 Bio-chemistry ND ND ND ND ND ND ND ND ND £ ND
Abbreviations: EEG = electroencephalogram; F = female; L = left; LL = lower limbs; M = male; mo=months; N = normal; NCS = nerve conduction studies; ND = not done; OU
= each eye; P = patient; R = right; S = spike; SLW = slow wave; UL = upper limbs; VEP = visual evoked potentials; WNL = within normal limits; y = year* Non-specific
generalized slow activity at 4-5y Hz with higher voltage, more on the occipital electrodes (during sleep). ** Excessive fast beta activity. Predominantly R occipital &
generalized epileptiform discharges. ***Moderately increased lipid droplets. Subsarcolemma accumulation of membranous material. § Enlargement of the sarcoplasmic
space between myofibrils associated with focal increase in granular and membranous material. £ Relatively low mitochondrial content.
doi: 10.1371/journal.pone.0076831.t003
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insertions) were predicted to lead to the nonsense mediated
mRNA decay (NMD) [Table 7]. The three missense mutations
are all affecting well conserved amino-acids. However,
p.H225Y mutation was predicted to be less severe (tolerated,
possibly damaging) compared to p.R591Q and p.G710R that
were predicted to be deleterious. In complementary DNA
investigations to identify molecular events other than missense
mutations causing-disease, MLPA detected no rearrangement
in both PLA2G6 and PANK2 genes.
Genotype Phenotype correlation
In order to find whether the genotype influences the
phenotype in our series of patients, we considered two relevant
criteria for assessing the severity of the pathology at the
functional disability level: (i) the age at onset of the disease
manifesting as ataxia, and (ii) the evolution of the disease at
the functional level. We expressed the results as a graph with
exponential trend curves. A curve of the evolution of the age at
onset of ataxia and a second one showing evolution of the age
at which patients reach functional Stage 7 (wheelchair bound)
were formulated. The disease duration was also considered in
the graph (Figure 7). We could distinguish two groups of
patients according to the age at onset and the age when
patients reached the functional disability Stage 7. Group 1,
whose age at onset was ≤ 15 months, reached Stage 7 very
rapidly, and the disease duration before reaching Stage 7 was
very short (zero to 5 years). Indeed, three patients (F1 [P1], F2
[P1] and [P2]) have never walked independently. The patient
whose disease progression was slower (F5 [P1]), was
wheelchair bound at 6 years, only 5 years after the onset of
ataxia. This patient manifested atypical INAD [Table 1]. Group
1, which includes 7 patients (Figure 7), is located in the lower
part of the curves. Group 2 consists of four patients from the
same family (F6), all with Karak syndrome. The age at onset of
ataxia in this group occurred between 3 and 6 years, at least
25 months later than the patient who manifested the disease
latest in Group 1 (F3 [P1], at age 15 months). Two patients (F6
[P1 and P2]) in Group 2 started the disease at age 6 years, the
same age when the patient with the slower disease
progression in Group 1 (F5 [P1]) became wheelchair-bound.
This group is in the exponential parts of the curves, reflecting
on one hand a greater disease duration before reaching Stage
7 (11 to 14.5 years) and on the other hand the slower
progression of the disease. In this group, there is also an
interfamilial variability in terms of age at onset of ataxia, and
pace of disease progression, even between the two sisters (F6
[P1 and P2]) whose disease started at age 6 years, but have
reached a functional Stage 7 later in the second decade at 17
and 20.5 years, respectively. Interestingly, patients of this
family are homozygous for the p.H225Y mutation predicted to
be relatively less severe, unlike the other missense as well as
the truncating mutations, in Group 1 (Table 7). The predicted
damaging mutations are responsible for a severe phenotype
characterized, at functional level, by a disease onset before the
age of 16 months and a fast progression confining all patients
to wheelchair before the age 6 years, either immediately after
onset of ataxia (F1 [P1], F2 [P1 and P2]), or 5 years later (F5
[P1]). The other symptoms showed no correlation with the
genotypes.
Table 5. Neuroimaging findings in 11 patients with PLA2G6 mutations.
Family
(Patient No.)  
Scan
type Age
Cerebellar
atrophy Low signal/density (globus pallidus) Low signal/density(substantia nigra) Cerebral white matter Corpus callosum
F1 (P1) MRI 3y 1 mo + + (DWI) + - -
 CT 4y 2 mo + - - - I
 MRI 4y 2 mo + + (T2, DWI) + - S
F2 (P2) MRI 1y 3 mo + - - H -
F2 (P1) MRI 3y 3 mo + + (DWI) - H -
F3 (P2) MRI 4y 4mo + + (T2, DWI) + H -
F3 (P1) MRI 10y 4mo + + (T2, DWI) + H -
F4 (P1) MRI 2y 10mo + + (DWI) - - -
F5 (P1) MRI 4y 2mo + - - - B
 MRI 7y 6 mo + + (T2, DWI) + H S
F6 (P3) MRI 17y 5mo + + (T2, DWI) + I -
F6 (P4) CT 19y + - - - I
F6 (P1) MRI 11y 4mo + + (T2) + I -
 MRI 21 y 3mo + + (T2) + H A -
F6 (P2) MRI 10y 4mo + + (T2) + - -
 MRI 13y 3mo + + (T2) + - -
+. Changes present; - changes absent
A = atrophy; B = changes borderline; DWI = diffusion-weighted MRI image; H = high (mild) T2- MRI signal in cerebral white matter; I = imaging quality or type not suitable to
assess feature; S = Simple splenium(posterior) corpus callosum; T2 = T2-MRI sequence.
doi: 10.1371/journal.pone.0076831.t005
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Figure 1.  Patient F2 (P1) MRI, age 3 years 3 months (A-D).  Coronal T2-weighted (A), axial T2-weighted (B), axial diffusion (C),
axial FLAIR (D) showing cerebellar atrophy (arrows) with widening of cerebellar folia (A), T2 normal signal intensity (arrows) of
globus pallidus (B), highlighted subtle iron deposition at globus pallidi (arrows) as reduction in signal intensity (C), and high signal
intensity (arrows) at cerebral white matter (D). Patient F2 (P2) MRI, age 1 year 3 months (E-H)). Coronal T2-weighted (E), axialT2-
weighted (F), axial diffusion (G), axial FLAIR (H) showing mild cerebellar atrophy (arrows) with mild widening of cerebellar folia (E),
normal signal intensity (arrows) of globus pallidus (F and G), and high signal intensity (arrows) at cerebral white matter (H).
doi: 10.1371/journal.pone.0076831.g001
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Figure 2.  Patient F5 (P1) MRI, age 4 years 2 months (A-D), and 7 years 6 months (E-H).  Sagittal T1-weighted (A and E),
coronal T2-weighted (B and F), axial T2-weighted (C and G) and axial diffusion (D and H) sequences showing mild cerebellar
cortical atrophy with mildly prominent folia (arrows in C). There is also simple corpus callosum (arrows in E). (F) Coronal T2-
weighted reveals progressive cerebellar cortical atrophy and gliosis, with widening of folia and increased signal in the residual
cerebellar cortex (arrow). Axial T2-weighted (G), and axial diffusion (H) sequences highlight iron deposition as reduction in signal
intensity in the globus pallidi (arrows).
doi: 10.1371/journal.pone.0076831.g002
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Discussion
The present cohort represents one of the largest collections
of patients from one country and the same ethnic background
(Arabs) with neurodegeneration associated with PLA2G6
mutations.
In the present study, 6 children (F1 [P1], F2 [P1 and P2], F3
[P1 and P2] and F4 [P1]) [Table 1] had classic INAD phenotype
with onset within the first 2 years of life, hyperreflexia and
tetraparesis (See Video S1) leading to loss of ambulation within
5 years [5,6], with ataxia being the earliest appearing symptom.
A seventh patient (F5 [P1]) [Table 1], manifested atypical NAD
with slower progression of the disease, ataxia and remarkable
spasticity, and contracture deformities of the lower limbs which
required surgical release. The phenotype of the remaining 4
patients from a single family (F6) [Table 1] is nearest to that of
Karak syndrome [1]. Indeed, onset ranged between 3-6 years
with ataxia, which was slowly progressive and associated with
slow cognitive decline. Loss of ambulation was at the age of 17
years in 3 patients whereas the fourth walked until 20.5 years
of age. The phenotype in the cohort we studied was relatively
heterogeneous as compared to the homogeneous spectrum in
14 previously reported children [5]. Despite the varying
phenotypes of the patients in the present study, ataxia was the
constant and earliest appearing symptom at a median age of
14 months (mean = 29.6 months). This was supported by
neuroimaging, which showed cerebellar cortical atrophy in all
patients, even at the age of 15 months.
Two patients with INAD phenotype manifested psychiatric
symptoms and three of 4 patients from family F6 (P1, P2 and
P4) had phobias, panic attacks and/or bouts of rage. This could
be explained by the involvement of the locus caeruleus in the
disease, which has been documented pathologically in patients
with PLA2G6 mutations [4]. It is noteworthy that the locus
caeruleus-noradrenergic system has been implicated in the
pathogenesis of panic disorder, post-traumatic disorders, and
several other psychiatric conditions [25-27].
In the present cohort, a female with Karak syndrome
phenotype (F6 [P1]) developed complex partial seizure at 21
years of age, which was confirmed by EEG. Another 2 siblings
Figure 3.  Patient F6 (P3) MRI, age 17 years 5 months.  Axial T2-weighted (A), axial gradient (B and C), sagittal T1-weighted (D)
and coronal fluid-attenuated inversion recovery (FLAIR, E) sequences highlight iron deposition as reduction in signal intensity in the
globus pallidi (arrows in A and B) and substantia nigra (arrow in C). There is also cerebellar cortical atrophy with increased CSF
spaces around the cerebellum (arrows in D and E).
doi: 10.1371/journal.pone.0076831.g003
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Figure 4.  Patient F1 (P1) MRI, age 3 years 1 month (A-D), and 4 years 2 months (E-H).  There is increased CSF space around
the cerebellum (arrows in A and E) associated with cerebellar cortical atrophy and gliosis, with widening of folia and increased
signal in the residual cerebellar cortex (arrows in B and F). Axial T2-weighted (C and G) and axial diffusion (D and H) highlight iron
deposition as reduction in signal intensity in the globus pallidi in only the later T2-weighted sequence (G), but in both diffusion
sequences (D and H).
doi: 10.1371/journal.pone.0076831.g004
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with INAD had brief tonic seizures with normal EEG in one and
non-specific changes in another. Fast rhythms on EEG were
observed in 2 patients with classic INAD without clinical
seizures [Table 3]. These fast rhythms are detected frequently
on EEG in patients with INAD, and generalized seizures
manifest in only a minority of cases [4-6,28,29].
Optic atrophy occurs in the majority of children with infantile
and atypical NAD whereas nystagmus and strabismus are also
common [4-6,28,29]. Saccadic eye movements were abnormal
in the two described siblings with Karak syndrome, but
fundoscopy revealed normal optic disks in both of them [1].
However, both patients are significantly younger than those
described in the present report.
Neurophysiologic studies revealed features of distal axonal
neuropathy in all 4 patients with Karak syndrome phenotype.
Also 3 of 5 (60%) children with classic INAD had features of
axonal neuropathy on NCS. This is similar to the findings in
other cohort of patients with INAD [4,5].
Similar to previous observations, the cerebellar atrophy was
the earliest and universal neuroimaging feature [4,5,28,29]. It
can usually be detected by MRI after the age of 2 years
[4,5,28,29] and even at a younger age by CT or MRI scans
[5,28]. It’s noteworthy that genetic knockdown of PLA2G6 in
mice (iPLA2b-/-) was documented to lead to the development
of cerebellar atrophy by the age of 13 months [30]. High signal
intensity, indicating gliosis, in cerebellar cortex (as seen in 60%
Figure 5.  Electron microscopic alterations in the muscle biopsy of patient F6 (P1), age 12 years.  (A and B) There is
enlargement of the sarcoplasmic space between myofibrils associated with focal increase in granular and membranous material
(arrows). The membranes are probably derived from the sarcoplasmic reticulum/myotubular system and from disintegrated
mitochondria. There were no myonuclear inclusions. (C and D) Electron microscopic analysis of the muscle biopsy of patient F1
(P1), age 3 years. (C) Lipid droplets (arrows) in muscle fibres are moderately increased in size and number. (D) Subsarcolemmal
accumulation of membranous material indicating proliferation of sarcoplasmic reticulum membranes.
doi: 10.1371/journal.pone.0076831.g005
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Figure 6.  Genetics findings.  Pedigrees (Ped) of the six Saudi Arabian families (F1-6) are represented in the same order as in the
tables and in Figure 7. Patients were also numbered according to the Tables. Haplotypes were reconstructed manually (Family F4
was not subjected to genotyping) and chromatograms of each identified mutation are shown, except Family F4 which had direct
sequencing in a private company. The segregation of the mutation, when possible, was shown for each pedigree with the
corresponding symbols (“+”= wild type and “-“= mutated).
doi: 10.1371/journal.pone.0076831.g006
Table 7. Nature and position of the mutations identified in the patients homozygous for the PLA2G6 locus markers.
Family  Exon  mutation
Tested in controls from
Maghreb*  
Exon Variant
Server  Computational Predictions
  mRNA level Protein level    SIFT ª PolyPhen2b
F3 13 c.1772GA p.R591Q 0/344 0/5357 Deleterious (0.03) Probably damaging (1.000)
F5 16 c.2218GA p.G740R 0/350 0/5235 Deleterious (0.00) Probably damaging (1.000)
F6 5 c.673CT p.H225Y 0/346 0/5354 Tolerated (0.17) Possibly damaging (0.632)
F1 8 c.1125delA p.E376WfsX14 0/172 0/5354    
F2 14 c.1911delC p.S637RfsX29 Not done 0/5352    
F4 14 c.1933CT p.R654X Not done 0/5352    
The mutations were annotated according to the HGVS recommendations. In Bold, the reported mutation4. Prot. = protein.
Score values are in brackets, they are between 0 and 1 for SIFT and PolyPhen2 software’s.
* Results are reported in number of chromosomes. a SIFT score: the scores closer to 0 are the most deleterious. b Scores closer to 1 indicate that the mutation is damaging.
doi: 10.1371/journal.pone.0076831.t007
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of the present cohort) is a frequent associated feature [4,5,28],
although not universally detected with INAD phenotype
[5,13,29,31]. Serial MRI in one patient in the present study
confirmed previous observations showing that cerebellar gliosis
subtly evolves with age and was associated with cerebral
atrophy after the age of 20 years [5,28,29]. Simple splenium
(posterior corpus callosum thinning) was evident in 2 patients
(F1 [P1] and F5 [P1]) and borderline changes were detected
initially in one of them (F5 [P1]). Similarly, one of 5 reported
patients [28] who had INAD with identified mutations in
PLA2G6 gene, had thinning of the corpus callosum depicted by
MRI at the age of 7 years. Also in a study on a cohort of
children with PLA2G6 gene mutations, all 12 patients with MRI
scans of sufficient quality had abnormal corpus callosum with
simple appearance to the splenium which was elongated, thin
and slightly vertically oriented [5]. A total of 82% of patients had
globus pallidus changes which were either initially present or
became apparent on subsequent T2 and/or diffusion weighted
imaging (DWI) MRI sequences. These changes were not
apparent on CT done at 19 years of age for one patient (F6
[P4]) and at 4.2 years for another (F1 [P1]). The latter child had
an earlier MRI at 3.1 years which revealed globus pallidus
hypointensity on DWI only (Figure 4). From the present
experience, DWI seems to precede T2-MRI sequence in
revealing the pallidal changes, since DWI facilitated the
detection of these alterations in another child (F4 [P1]) who had
MRI at the age of 2.8 years (Table 5). T2 gradient MRI
sequence is also more sensitive than T2 in depicting iron
deposition in the globus pallidus, but was undertaken in only
one patient (Figure 3). The eye-of-the-tiger sign, reported in the
2 patients with Karak syndrome [1] was not seen in any of the
patients in this cohort. Similar to another study [5], longitudinal
imaging data revealed iron deposition (manifesting as low
signal/density) in the substancia nigra in all patients after the
age of 5 years, and iron accumulation also seemed to become
more appreciable later in the course of the disease [6].
The muscle biopsies were done in 4 patients to exclude
mitochondrial disease and their standard histological
characterization revealed non-specific neurogenic features.
However, an unexpected feature of the study derives from
muscle electron microscopy where focal increase in granular
and membranous material was observed in 2 patients (F1 [P1]
with classic INAD and F6 [P1] with Karak syndrome
Table 6. Allegro software results of Multipoint LOD score
values of four markers flanking the PLA2G6 gene.
 Microsatellite Markers D22S1177 D22S1045 D22S272 D22S428  
 relative position in cM 49.33 50.57 52.56 53.85  
Family F1 0.0804 0.9257 1.4307 0.8841  
 F2 1.3838 1.2315 0.000 1.1293  
 F3 2.1577 1.0507 2.1577 1.9122  
 F5 0.9309 0.7270 0.7848 0.6854  
 F6 3.2045 1.5882 3.3977 -∞  
 LOD score values  
The maximum LOD score values for each family are indicated by bold characters,
doi: 10.1371/journal.pone.0076831.t006
phenotype). This membranous material is probably derived
from the sarcoplasmic reticulum/myotubular system and could
have resulted from the disrupted membrane homeostasis
following disruption of iPLA2-VIA encoded by PLA2G6 gene.
iPLA2 is essential for maintenance and repair of cellular
membranes because of its requirement for phospholipid
remodelling [32]. To the best of our knowledge, the
ultrastructural findings described here have not been reported
previously in cases of neurodegeneration associated with
PLA2G6 mutations. On the other hand, biochemical analysis of
the muscle biopsy of a patient with Karak syndrome phenotype
(F6 [P1], taken at the age of 12 years) showed a relatively low
mitochondrial content in the muscle. This is compatible with the
observed ultrastructural abnormalities seen by electron
microscopy, and is also in agreement with the proposed role of
PLA2G6 in protecting the mitochondrial membrane from
peroxidation [33].
This is the first time that such a genotype phenotype
correlation was highlighted in a cohort of PLAN patients, even
in studies which included a group of patients belonging to the
same ethnic background. Indeed, in the reported series [5],
there was no evidence of genotype phenotype correlation for
the same mutation (p.K545T) which has been identified at
homozygous state in 9 out of 11 Pakistani patients. In the
present study, apart from the onset of ataxia and evolution of
functional disability, phenotypic variability has also manifested
in all other evaluated clinical symptoms and signs. This
demonstrates that other factors are involved in modulation of
the variability of the broad clinical spectrum of PLAN.
In conclusion, we describe the phenotypic and genetic
spectrum of 11 patients followed for a maximum period of 17
years and report six underlying PLA2G6 gene mutations, five of
which are novel. We have shown that the phenotype of
neurodegeneration associated with PLA2G6 mutations is
variable in this cohort of patients who belong to the same
ethnic background but, in terms of functional disability, was
influenced by the genotype. Nevertheless, cerebellar atrophy is
the constant and earliest feature of the disease, and precedes
brain iron accumulation, leading to the provisional diagnosis of
a recessive progressive ataxia in these patients. It is
noteworthy that variable combinations of sites of degeneration
and associated symptoms are often observed in childhood-
onset recessive ataxias including epilepsy and abnormal
cognition [34-36]. Electron microscopy showed, in 2 patients,
an unexpected feature of focal increase in granular and
membranous material probably derived from the sarcoplasmic
reticulum/myotubular system. Biochemical analysis of the
muscle biopsy of a patient showed a relatively low
mitochondrial content in the muscle. This other new finding is
compatible with the ultrastructural abnormalities seen by EM,
and is also in agreement with the proposed role of PLA2G6 in
protecting the mitochondrial membrane from peroxidation.
Molecular testing for PLA2G6 mutations is, therefore, indicated
in childhood-onset ataxia syndromes, if neuroimaging shows
cerebellar atrophy with or without evidence of brain iron
accumulation. Considering the age at onset and the functional
disability, there is an evidence of genotype-phenotype
correlation. However, the wide intra- and inter-familial variability
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Figure 7.  Genotype-phenotype correlation.  Graphic representation of the evolution exponential tendency curves of the
functional disability (red curve and red squares) and of the age at onset of ataxia (blue curve and blue squares) which both seem to
depend on the nature of the mutation. Each number in X axis corresponds to one patient. Below this axis are indicated the codes of
patients (from Families 1 to 6) and the corresponding mutation. Y axis corresponds to the age per years. Two groups are identified
(dashed ellipses) depending on the age at onset of ataxia. The first one encompasses the patients with ataxia manifesting at or
before 15 months of age, and the second one, patients with an onset between 3 and 6 years. The age when becoming wheelchair-
bound (red squares) and the disease duration (green triangles) are most prominent clusters in the second group. Abbreviations: wb
= wheelchair-bound. Expon = exponential.
doi: 10.1371/journal.pone.0076831.g007
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of the disease in physiological, psychiatric and other clinical
aspects, cannot be explained only by single homozygous
mutations in the PLA2G6 gene. At least, other environmental
and/or genetic factors (other variants in the genome,
epigenetics, etc.) might probably modulate the disease
presentation.
Supporting Information
Video S1.  Patient F2 (P2) with INAD, aged 2.4 years,
showing tetraparesis and brisk reflexes (including
adductor reflex) despite absence of leg stiffness (note the
frog position of the lower limbs).
(WMA)
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